Format

Send to

Choose Destination
Rev Recent Clin Trials. 2016;11(3):260-5.

QT Prolongation and Anticancer Drugs: Is it a Cardiologist's Worry? The Oncologist's Point of View.

Author information

1
UO di Oncologia, Fondazione Poliambulanza, Via Bissolati 57, 25124, Brescia, Italy.

Abstract

Currently, many novel therapies are available for physicians treating cancer; some of them are associated with adverse cardiac events. One of the most worrisome cardiac event is QT prolongation, which is a risk factor for developing the potentially fatal torsade de pointe. Many classes of drugs, both anticancer and concomitant agents, are involved in this issue. We report a review of old and new commonly used agents with torsadogenic potential.

PMID:
26917017
[Indexed for MEDLINE]

Supplemental Content

Full text links

Icon for Bentham Science Publishers Ltd.
Loading ...
Support Center